JAGSNPHARMPharmaceuticals
Jagsonpal Pharmaceuticals Ltd — Profit & Loss Statement
₹184.03
+0.05%
Jagsonpal Pharmaceuticals Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Reconciled Cost Of Revenue | 96.44 Cr | 79.98 Cr | 92.51 Cr | 89.28 Cr | — |
| EBITDA | 78.95 Cr | 32.35 Cr | 36.26 Cr | 28.43 Cr | — |
| EBIT | 70.82 Cr | 30.68 Cr | 35.09 Cr | 26.90 Cr | — |
| Net Interest Income | -0.96 Cr | -0.81 Cr | 3.02 Cr | 1.26 Cr | — |
| Interest Expense | 0.96 Cr | 0.81 Cr | 0.28 Cr | 0.26 Cr | — |
| Normalized Income | 39.76 Cr | 22.46 Cr | 29.04 Cr | 19.19 Cr | — |
| Net Income From Continuing And Discontinued Operation | 55.36 Cr | 22.46 Cr | 26.72 Cr | 18.86 Cr | — |
| Total Expenses | 225.78 Cr | 187.30 Cr | 202.38 Cr | 193.04 Cr | — |
| Diluted Average Shares | 6.73 Cr | 6.63 Cr | 6.55 Cr | 6.55 Cr | — |
| Basic Average Shares | 6.70 Cr | 6.61 Cr | 6.55 Cr | 6.55 Cr | — |
| Diluted EPS | 8.22 | 3.39 | 4.08 | 2.88 | — |
| Basic EPS | 8.26 | 3.40 | 4.08 | 2.88 | — |
| Diluted NI Availto Com Stockholders | 55.36 Cr | 22.46 Cr | 26.72 Cr | 18.86 Cr | — |
| Net Income Common Stockholders | 55.36 Cr | 22.46 Cr | 26.72 Cr | 18.86 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 55.36 Cr | 22.46 Cr | 26.72 Cr | 18.86 Cr | — |
| Net Income Including Noncontrolling Interests | 55.36 Cr | 22.46 Cr | 26.72 Cr | 18.86 Cr | — |
| Net Income Continuous Operations | 55.36 Cr | 22.46 Cr | 26.72 Cr | 18.86 Cr | — |
| Tax Provision | 14.50 Cr | 7.41 Cr | 8.09 Cr | 7.79 Cr | — |
| Pretax Income | 69.86 Cr | 29.87 Cr | 34.81 Cr | 26.64 Cr | — |
| Other Non Operating Income Expenses | 8.19 Cr | 9.28 Cr | 0.45 Cr | 0.17 Cr | — |
| Special Income Charges | 19.69 Cr | 0.00 | -3.13 Cr | 0.04 Cr | — |
| Net Non Operating Interest Income Expense | -0.96 Cr | -0.81 Cr | 3.02 Cr | 1.26 Cr | — |
| Interest Expense Non Operating | 0.96 Cr | 0.81 Cr | 0.28 Cr | 0.26 Cr | — |
| Operating Income | 42.94 Cr | 21.40 Cr | 34.33 Cr | 24.55 Cr | — |
| Operating Expense | 129.34 Cr | 107.32 Cr | 109.87 Cr | 103.76 Cr | — |
| Other Operating Expenses | 50.27 Cr | 43.57 Cr | 18.56 Cr | 18.03 Cr | — |
| Depreciation And Amortization In Income Statement | 8.13 Cr | 1.66 Cr | 1.18 Cr | 1.53 Cr | — |
| Depreciation Income Statement | 8.13 Cr | 1.66 Cr | 1.18 Cr | 1.53 Cr | — |
| Gross Profit | 172.28 Cr | 128.72 Cr | 144.20 Cr | 128.30 Cr | — |
| Cost Of Revenue | 96.44 Cr | 79.98 Cr | 92.51 Cr | 89.28 Cr | — |
| Total Revenue | 268.72 Cr | 208.70 Cr | 236.71 Cr | 217.58 Cr | — |
| Operating Revenue | 268.72 Cr | 208.70 Cr | 236.71 Cr | 217.58 Cr | — |
| Tax Effect Of Unusual Items | 4.09 Cr | 0.00 | -0.69 Cr | -0.14 Cr | — |
| Tax Rate For Calcs | 0.21 | 0.25 | 0.23 | 0.29 | — |
| Normalized EBITDA | 59.26 Cr | 32.35 Cr | 39.21 Cr | 28.90 Cr | — |
| Total Unusual Items | 19.69 Cr | 0.00 | -2.95 Cr | -0.47 Cr | — |
| Total Unusual Items Excluding Goodwill | 19.69 Cr | 0.00 | -2.98 Cr | -0.47 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 55.36 Cr | 22.46 Cr | 26.72 Cr | 18.86 Cr | — |
| Reconciled Depreciation | 8.13 Cr | 1.66 Cr | 1.18 Cr | 1.53 Cr | — |
| Interest Income | — | 8.59 Cr | 3.43 Cr | 1.55 Cr | 2.99 Cr |
| Rent Expense Supplemental | — | 0.91 Cr | 1.83 Cr | 2.48 Cr | 2.27 Cr |
| Total Other Finance Cost | — | 0.04 Cr | 0.14 Cr | 0.02 Cr | 0.09 Cr |
| Interest Income Non Operating | — | 8.59 Cr | 3.43 Cr | 1.55 Cr | 2.99 Cr |
| Selling General And Administration | — | 20.14 Cr | 23.47 Cr | 24.05 Cr | 17.26 Cr |
| Selling And Marketing Expense | — | 16.34 Cr | 17.87 Cr | 13.88 Cr | 12.99 Cr |
| General And Administrative Expense | — | 3.81 Cr | 5.59 Cr | 10.17 Cr | 4.27 Cr |
| Rent And Landing Fees | — | 0.91 Cr | 1.83 Cr | 2.48 Cr | 2.27 Cr |
| Other Special Charges | — | — | 3.10 Cr | -0.09 Cr | — |
| Write Off | — | — | 0.26 Cr | 0.04 Cr | — |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Jagsonpal Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.